Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.

Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.

But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.

Opdualag chalks up another failure, this time in the extension of an approved use.

But the overall survival benefit in prostate cancer is still driven by HRR mutations.

Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.

AbbVie follows Gilead in throwing Xilio a lifeline.

The deal isn’t done, but would be Merck’s biggest oncology buy.

Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.

Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.